Primary Cells Market Poised to Witness a Strong Growth over 2023

Pune, India, May 2019, MRFR Press Release/- Market Research Future has Published a Half-Cooked Research Report on the Global Primary Cells Market.

Market Overview

The global primary cells market to exhibit a strong growth between 2018 and 2023. Market Research Future (MRFR) reports that the global primary cells market is poised to at a compound annual growth rate (CAGR) of 9.5% during the projection period. Advanced and safe mechanical or enzymatic method are used to isolate cells from human or blood cells. Primary cells are engaged in a vast category of cell-based research owing to their pertinent cellular functions.

Increased research activities focused on biopharmaceutical discovery and biotechnology, increased investment in cancer research, growing demand for monoclonal antibodies and higher healthcare expenditure are some of the key factor influencing the global primary cells market. Primary human cells are preferred over cell lines which also remains a positive factor. Unlike endothelial cell lines, endothelial cells retain most functional markers. Primary cells being a novel technology is relatively more expensive. At the same time, issue of cell contamination is yet to be effectively addressed.

Segmental Overview

MRFR’s report includes an in-depth segmental analysis of the global primary cell market based on type, origin and end user.

Based on type, the market has been segmented into animal primary cells and human primary cells. Based on origin, the market has been segmented into hematopoietic cells, liver cells, renal cells, skeletal and muscle cells, skin cells, gastrointestinal cells, lung cells, heart and others. Based on end-user, the market has been segmented into life science research companies and research institutes.

Competitive Landscape  

Some of the leading companies operating in the global Cell Biologics (US), ZenBio, Inc. (US), ALLCells (US), Axol Biosciences (UK), Thermo Fisher Scientific (US), Merck KGaA (Germany), Lonza (Switzerland), American Type Culture Collection (ATCC) (US), Promocell (Germany) and STEMCELL Technologies (Canada).

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/primary-cells-market-6296

Global Primary Cells Market: Regional Segmentation

Based on region, the market has been segmented into Europe, Americas, the Middle East and Africa (MEA), and Asia Pacific (APAC). The Americas cells market cover both South America and North America. The Europe primary cells market covers Eastern Europe and Western Europe. Key countries covered in the Asia Pacific primary cells market include China, South Korea, Japan, Australia, and India. In terms of revenue, North America and South America collectively dominate the global primary cells market. Some of the key factors supporting the growth of the market in Americas include strong government backing for R&D, easy access to latest medical technologies and increased prevalence of cancer. Data released by National Cancer Institute revealed that nearly 1,685,210 new cases of cancer were recorded in the US in 2016.

Europe in holds the second spot in terms of value. Healthcare remains a major area of focus for the EU. Over the years, several policies have been launched to improve health care services in the region. Advanced countries in Europe present attractive growth opportunities for market players. In 2016, the gross domestic expenditure on R&D activities was more than Euro 33 Bn as per the office for National Statistics.

APAC is viewed as an emerging market for primary cells. The healthcare sector in APAC is witnessing tremendous growth, which is translating into opportunities for market players. Rising number of cancer cases, introduction favourable policies and pharmaceutical outsourcing are some of the factors supporting the market growth in APAC. Spending on medical science R&D institutes have surged in countries such as China and India, which is paving the way for the market to growth. The market in MEA is also expected to grow at a healthy pace but from a lower base. Many of the countries in MEA face issues such as underdeveloped healthcare infrastructure, limited access to services, etc.